BNO — Bionomics Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- AU$14.69m
- -AU$15.40m
- AU$0.26m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.4 | ||
| Price to Tang. Book | 0.76 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 72.43 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.72% | ||
| Return on Equity | -46.14% | ||
| Operating Margin | -10128.99% | ||
Financial Summary
| Year End 30th Jun | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3.95 | 0.91 | 0.05 | n/a | 0.26 | 7.14 | 8.7 | -57.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bionomics Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with unmet medical needs. The Company operates in the drug development segment in Australia. The Company is advancing its lead drug candidate, BNC210, which is an oral, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. It also includes a pre-clinical CNS pipeline that has two earlier-stage small molecule discovery programs targeting ion channels and representing opportunities for clinical programs.
Directors
- Errol De Souza CHM (67)
- Adrian Hinton CFO
- Connor Bernstein VPR
- Liz Doolin VPR
- Suzanne Irwin SEC
- Peter Davies NED
- Alan Fisher NED
- Jane Ryan NED
- Aaron Weaver NED
- David Wilson NED
- Last Annual
- June 30th, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- September 27th, 1996
- Public Since
- December 21st, 1999
- No. of Shareholders
- 5,941
- No. of Employees
- 140
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,468,735,424
- Address
- 200 Greenhill Road, THEBARTON, 5063
- Web
- https://www.bionomics.com.au/
- Phone
- +61 881507400
- Auditors
- Ernst & Young
Upcoming Events for BNO
Similar to BNO
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
FAQ
What is the Bionomics share price?
As of Today at 01:04 UTC, shares in Bionomics are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Bionomics share price performed this year?
Shares in Bionomics last closed at AU$0.01 and the price had moved by -75% over the past 365 days. In terms of relative price strength the Bionomics share price has underperformed the ASX All Ordinaries Index by -76.75% over the past year.
What are the analyst and broker recommendations for Bionomics?
The overall consensus recommendation for Bionomics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Bionomics dividend yield?
Bionomics does not currently pay a dividend.
Does Bionomics pay a dividend?
Bionomics does not currently pay a dividend.
When does Bionomics next pay dividends?
Bionomics does not currently pay a dividend.
How do I buy Bionomics shares?
To buy shares in Bionomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bionomics?
As of the previous close price of AU$0.01, shares in Bionomics had a market capitalisation of AU$19.09m.
Where are Bionomics shares listed?
Here are the trading details for Bionomics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: BNO
What kind of share is Bionomics?
Based on an overall assessment of its quality, value and momentum Bionomics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bionomics share price forecast for 2023?
The analyst consensus target price for shares in Bionomics is AU$23.00. That is 176823.08% above the last closing price of AU$0.01.
Analysts covering Bionomics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.02 for the next financial year.
Find out moreWhat is the trend in the Bionomics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionomics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -55.78%.
As of the last closing price of AU$0.01, shares in Bionomics were trading -62.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bionomics PE Ratio?
The Bionomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bionomics?
Bionomics' management team is headed by:
- Errol De Souza - CHM
- Adrian Hinton - CFO
- Connor Bernstein - VPR
- Liz Doolin - VPR
- Suzanne Irwin - SEC
- Peter Davies - NED
- Alan Fisher - NED
- Jane Ryan - NED
- Aaron Weaver - NED
- David Wilson - NED